Synergy Pharmaceuticals Inc. (SGYP)

1.63
NASDAQ : Health Technology
Prev Close 1.68
Day Low/High 1.61 / 1.69
52 Wk Low/High 1.43 / 4.84
Avg Volume 3.70M
Exchange NASDAQ
Shares Outstanding 246.74M
Market Cap 414.52M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Synergy Pharmaceuticals Inc. Of Class Action Lawsuit And Upcoming Deadline - SGYP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Synergy Pharmaceuticals Inc. Of Class Action Lawsuit And Upcoming Deadline - SGYP

Pomerantz LLP announces that a class action lawsuit has been filed against Synergy Pharmaceuticals Inc.

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of...

3 Favorite Biotech Stocks for the Second Quarter

3 Favorite Biotech Stocks for the Second Quarter

Your questions are answered in our latest addition of the biotech mailbag.

Synergy Pharmaceuticals To Present At Oppenheimer 28th Annual Healthcare Conference

Synergy Pharmaceuticals To Present At Oppenheimer 28th Annual Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28 th Annual Healthcare Conference on Tuesday,...

My Biotech Mailbag Is Back

My Biotech Mailbag Is Back

I'll answer some of frequent questions I am hearing from readers in recent weeks.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Synergy Pharmaceuticals Inc.

The Klein Law Firm Reminds Investors Of The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm Reminds Investors Of The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Synergy Pharmaceuticals Inc.

SGYP EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

SGYP EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Synergy Pharmaceuticals...

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Business Update

Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

The Klein Law Firm Announces The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm Announces The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Synergy Pharmaceuticals...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of...

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc. (SGYP)

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc. (SGYP)

The Klein Law Firm announces the commencement of an investigation of Synergy Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Synergy Pharmaceuticals Inc.

SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm

SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synergy Pharmaceuticals, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc.

The Klein Law Firm announces the commencement of an investigation of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc.

SGYP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

SGYP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the Compensation Committee of the Board...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. - SGYP

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. - SGYP

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Synergy Pharmaceuticals Inc.